How to Evaluate Stem Cell and Regenerative Medicine Claims: An NYC Physician's Guide to Evidence, FDA Rules, and Red Flags

Regenerative medicine has moved from research journals into strip-mall clinics, wellness podcasts, and Instagram ads. Some of what is being sold is legitimate, carefully practiced medicine. Some of it is expensive theater. For a patient in pain — or facing a joint replacement, or watching their hair thin — the hardest part is not deciding whether to try regenerative medicine. It is figuring out who to believe.

This guide is written to give you a practical framework for evaluating stem cell and regenerative medicine claims: what the evidence actually supports today, how U.S. regulation defines the boundaries, and the specific red flags that separate a responsible clinic from a marketing operation. Dr. Ajit Dhaliwal practices regenerative medicine at Regen Health Physicians in New York City and Salt Lake City, and the standards below are the same ones we apply to our own treatment recommendations.

Start With the Right Question

Most patients begin by asking, "Does stem cell therapy work?" That question is too broad to answer. Regenerative medicine is not one treatment — it is a category that includes platelet-rich plasma (PRP), bone-marrow and adipose-derived cell preparations, Muse cells, exosome products, prolotherapy, and peptide protocols. Each has its own biology, its own evidence base, and its own appropriate indications.

The better question is narrower and has four parts:

1. For my specific condition — not "joint pain," but moderate knee osteoarthritis with intact joint space or chronic gluteal tendinopathy;
2. with this specific preparation — leukocyte-poor PRP, bone marrow concentrate, and an exosome vial are not interchangeable;
3. compared to what — physical therapy, a corticosteroid injection, surgery, or doing nothing;
4. with what realistic magnitude of benefit — pain reduction and improved function, not "regrowing a knee."

A clinician who reframes your question this way is doing their job. A clinician who answers "yes, it works for everything" is selling.

What the Evidence Actually Supports Today

Regenerative medicine's evidence base is uneven — genuinely strong in some places, promising but immature in others, and essentially absent in a few areas that are nonetheless marketed aggressively.

Reasonably well supported

PRP for knee osteoarthritis. This is the most studied application. Multiple randomized trials and meta-analyses have compared intra-articular PRP with hyaluronic acid, corticosteroid, and saline, and the pooled signal favors PRP for pain and function at 6–12 months, particularly in mild-to-moderate disease. Effects are not universal and are smaller in advanced, bone-on-bone arthritis.

PRP for chronic tendinopathy. Lateral elbow tendinopathy ("tennis elbow") has the most consistent data; patellar and gluteal tendinopathy have supportive trials. The mechanism is plausible: chronic tendinopathy is a failed-healing state with degenerated collagen and poor vascularity rather than a simple inflammatory one, and concentrated platelets deliver growth factors (PDGF, TGF-β, VEGF, IGF-1) that restart a stalled repair cascade. If you want the practical version of that, see our breakdown of the week-by-week tendon healing timeline after PRP.

PRP for androgenetic alopecia. Randomized and split-scalp studies show measurable increases in hair count and density with a proper induction series, best in early-to-moderate loss where follicles are miniaturized but not scarred over. This is why we assess candidacy before recommending precision hair restoration rather than treating every case of thinning the same way.

Promising but still maturing

Bone marrow aspirate concentrate for osteoarthritis and certain cartilage lesions, Muse cell therapy, and exosome-based products fall here. Muse cells (multilineage-differentiating stress enduring cells) are a distinct, naturally occurring population that migrate toward damaged tissue via sphingosine-1-phosphate signaling and differentiate according to the local environment — biologically elegant, with early human trials in stroke, myocardial infarction, and spinal cord injury. That is a legitimate reason for interest. It is not a license to promise outcomes. Where a therapy sits in the pipeline should be stated plainly, and we hold Muse and other cell therapies to that standard when we discuss them with patients.

Not supported by current evidence

Claims that any injectable will reverse severe end-stage arthritis, regrow a fully absent joint surface, cure autoimmune disease outright, or reverse neurodegeneration are not supported. Neither are "stem cell IV drips" marketed as general anti-aging. If a clinic markets one product as effective for arthritis, autism, COPD, Alzheimer's, and erectile dysfunction simultaneously, the breadth of the claim is itself the evidence that something is wrong.

The FDA Rules, in Plain Language

You do not need to be a regulatory expert, but understanding one distinction filters out a large share of bad actors.

The FDA regulates human cells and tissues under 21 CFR Part 1271. A product can be handled under the lighter-touch "361 HCT/P" pathway only if it meets several criteria, the most important being that it is minimally manipulated and used for a homologous function — the same basic function in the recipient that it served in the donor. Products that fail those criteria are drugs or biologics, and they require an Investigational New Drug application and FDA approval before marketing.

Practically, this means:

• Autologous, same-day, minimally processed preparations — your own blood spun into PRP, your own bone marrow aspirated and concentrated in one sitting — generally sit inside the lighter pathway.
• Culture-expanded cells (grown in a lab over days or weeks) are drugs. Any U.S. clinic offering culture-expanded stem cell injections outside an authorized clinical trial is operating outside the rules.
• Umbilical cord, amniotic, and "young donor" allogeneic products marketed as containing live, functional stem cells are the highest-risk category. Independent laboratory analyses of commercially sold cord-blood and amniotic products have repeatedly found few or no viable stem cells, and the FDA has issued warning letters and safety communications after infections traced to contaminated products.
• Exosome products have no FDA-approved indication in the U.S. They may be used thoughtfully, but they should be presented as investigational, not as a superior upgrade you pay extra for.

Also know what "FDA registered" means: registering a facility or listing a product is an administrative step. It is not approval, and clinics that blur the two in their marketing are doing so on purpose.

Fourteen Red Flags

Any single item below can have a benign explanation. Two or more together should stop you.

About the claims

1. One treatment marketed for a long, unrelated list of conditions.
2. Guarantees, "cures," or specific success percentages with no citation.
3. Before-and-after photos with no timeframe, protocol, or disclosure of concurrent treatments.
4. "FDA registered" or "FDA compliant" used to imply approval.

About the evidence

1. Only testimonials — no published literature, no trial registry numbers.
2. Claims that the medical establishment is "suppressing" the therapy.
3. Citing animal or in-vitro data as if it were human outcome data.

About the process

1. No physician evaluation before a treatment plan is quoted; a salesperson quotes the price.
2. No imaging or lab workup for a structural problem.
3. No discussion of alternatives, including conservative care and surgery.
4. Pressure tactics: today-only pricing, deposits before consultation, financing pushed hard.
5. Large prepaid packages of many injections purchased before any response is assessed.

About accountability

1. Vague sourcing — nobody can tell you exactly what is in the vial, its origin, and its processing.
2. No defined follow-up, no outcome measures, and no plan for what happens if it does not work.

Nine Questions to Ask at the Consultation

Bring these. Good clinicians welcome them.

1. What exactly are you injecting — autologous or donor, minimally manipulated or culture-expanded?
2. Under which regulatory pathway is this offered, and is it part of a registered trial?
3. What is the published evidence for this preparation in my condition?
4. What response rate do you see in patients like me, and how do you measure it?
5. What are the alternatives, and why is this better for me right now?
6. Who performs the injection, and is it image-guided?
7. What is the full cost, including follow-up and any repeat treatment?
8. What does the recovery timeline look like, and what activity restrictions apply?
9. At what point would you tell me this is not working and recommend something else?

The last question is the most diagnostic. A physician with a defined stopping point is practicing medicine. A clinic whose answer to a poor result is always "you need more sessions" is running a subscription.

What a Responsible Regenerative Workup Looks Like

For comparison, here is the sequence a careful evaluation follows — the same one we use at our NYC and Salt Lake City practices.

History and functional assessment. Mechanism of injury, symptom duration, prior treatments and their results, what specific activities are limited, and your actual goal (returning to running is a different target than sleeping through the night).

Imaging when structure matters. Grading arthritis, confirming a tendon or labral lesion, and — importantly — identifying cases where regenerative treatment is unlikely to help and surgical referral is the honest answer. Not every patient is a candidate, and being told so is a good sign.

Systemic contributors. Healing is metabolic. Uncontrolled blood sugar, poor sleep, low vitamin D, smoking, thyroid dysfunction, and untreated hormonal deficits all blunt the response to any regenerative injection. This is why our approach connects orthopedic care with chronic disease and metabolic management rather than treating a joint in isolation.

A specific, staged plan. Which preparation, how many treatments, what interval, what rehabilitation protocol runs alongside it, and what reassessment happens at 6 and 12 weeks. Adjunctive tools such as targeted peptide protocols or hormone optimization are layered in only where there is a defined rationale.

Rehabilitation, not rest alone. Progressive loading after tendon and joint treatment is not optional. A clinic that injects and sends you home without a loading program is delivering half a treatment.

The Honest Middle Ground

The most useful posture is neither uncritical enthusiasm nor blanket dismissal. Regenerative medicine offers real, measurable benefit for a defined set of musculoskeletal and dermatologic problems, and an expanding — but not yet mature — set of possibilities elsewhere. The patients who do best are the ones who arrive with a specific diagnosis, realistic expectations, a physician willing to say "you are not a candidate," and a rehabilitation plan they actually follow.

If you are weighing an offer you have received, or you want a straight assessment of whether regenerative treatment fits your situation, our team is glad to review your imaging and history. You can read more about Dr. Dhaliwal's approach and philosophy, browse our joint and orthopedic services, or book a consultation with our NYC or Salt Lake City office.

---

Medical disclaimer: This article is for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Regenerative therapies are not appropriate for every patient, and outcomes vary. Some treatments discussed are considered investigational and are not FDA-approved for the indications mentioned. Always consult a qualified physician about your individual circumstances.